The Change Initiative Prevention Programme, delivered in partnership with leading global actors, aims to reframe prevention as a smart, cross-sector investment in resilience. We're exploring how ...

Ultimately the plan will be judged by its real-world impact on health outcomes. At this years’ OHE Annual Lecture in September, Professor Anita Charlesworth will offer reflections on the economic ...

New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this market failure, providing ...

In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of ...

In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine ...

In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced ...

In a bid to reduce health care budgets, policymakers and healthcare professionals are increasingly looking to prevention strategies.

Real-World Evidence (RWE) can provide decision-makers in the healthcare sector with insights into the functioning of health technologies outside of clinical trial settings. In this report, we focus on ...

The value of antibiotics often extends beyond what HTA captures. The STEDI framework aims to capture that broader value and our report outlines a roadmap to realising its full potential.

In England, an estimated 378,427 people receive palliative care each year in a range of specialised and generalised services. Overall, the quality of palliative care in England and the wider UK is ...

In our Around the World in HTAs insight series we shed light on HTA successes and challenges around the world. In this edition, Sarin KC, Manit Sittimart, Chittawan Poonsiri, Yi Wang, and Simon ...

In this report, we explore the status of access and uptake for NGS testing for lung cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for ...